1. Home
  2. GCT vs ORKA Comparison

GCT vs ORKA Comparison

Compare GCT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCT

GigaCloud Technology Inc

HOLD

Current Price

$43.80

Market Cap

1.6B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$45.54

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCT
ORKA
Founded
2019
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GCT
ORKA
Price
$43.80
$45.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
12
Target Price
$33.00
$57.25
AVG Volume (30 Days)
708.1K
504.1K
Earning Date
05-11-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
17.70
N/A
EPS
3.59
N/A
Revenue
$1,161,042,000.00
N/A
Revenue This Year
$14.43
N/A
Revenue Next Year
$6.78
N/A
P/E Ratio
$12.46
N/A
Revenue Growth
64.96
N/A
52 Week Low
$11.17
$5.49
52 Week High
$48.00
$45.52

Technical Indicators

Market Signals
Indicator
GCT
ORKA
Relative Strength Index (RSI) 55.45 69.55
Support Level $37.46 $26.02
Resistance Level $44.01 N/A
Average True Range (ATR) 2.26 3.21
MACD 0.03 0.73
Stochastic Oscillator 73.90 89.39

Price Performance

Historical Comparison
GCT
ORKA

About GCT GigaCloud Technology Inc

GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: